HealthMore in Health→
Bayer Agrees to Buy Perfuse Therapeutics in $300 Million Upfront Deal
Key Takeaways
- Bayer will pay $300 million upfront to acquire Perfuse Therapeutics.
- The deal centers on a mid-stage ophthalmology program.
- The program is described as targeting leading causes of blindness.
DE
DT Editorial Team··via endpoints.news